Cell Rep Med September 2025 PMID 40912255

Effect of henagliflozin on aging biomarkers in patients with type 2 diabetes: A multicenter, randomized, double-blind, placebo-controlled study.

Jie Zhang, Wei Cai, Danfeng Liu, Nianfeng Zheng, Youping Wang, Fenglin Qiu, Huoping Zheng, Huaxia Gan, Yuqing Huang, Yan Zhou, Meiling Yu, Shuping Xiong, Guigen Luo, Jianping Guo, Lingyan Zhu

Mentions

28
Peak: 16 in Sep 2025
across 6 sources since Sep 2025

Extended reach

83,090
potential audience

Total likes

1,144

Video views

18,356

Mentions per month

Sep 2025 – Nov 2025

Where it's discussed

  • X / Twitter14 posts
  • News6 articles
  • Bluesky2 posts
  • YouTube2 videos
  • Facebook2 posts
  • Blogs2 articles

AI synopsis

What people are saying

The discussions demonstrate high engagement with posts mentioning the promising effects of henagliflozin, such as increased telomere length and immune benefits, using words like 'significant,' 'potential,' and 'promising,' which convey both enthusiasm and cautious optimism about its anti-aging implications.

AgreementModerate agreement

Most posts support or acknowledge the potential benefits of the study, with some expressing cautious optimism about its findings.

InterestHigh interest

Discussions show high interest, often highlighting promising results and potential implications for anti-aging treatments.

EngagementModerate engagement

Posts include references to study details, interpret their implications, and emphasize the importance of the findings, reflecting moderate engagement.

ImpactModerate impact

There is recognition that this research could influence future treatment approaches, though some note the need for further validation.

Abstract in brief

  • Sodium-glucose cotransporter-2 inhibitors, like henagliflozin, may mimic caloric restriction and show potential anti-aging effects, but more clinical data are needed.
  • In a study involving 150 participants with type 2 diabetes, those taking henagliflozin for 26 weeks showed significant increases in telomere length and improvements in glucose metabolism compared to placebo.
  • Immune and metabolomic analyses indicated that henagliflozin enhances certain immune cell functions and increases levels of crucial metabolites, pointing to its possible multiple pathways for anti-aging effects.

Top posts

Most liked on X and Bluesky
Aging Science News
@AgingBiology · X

Effect of henagliflozin on aging biomarkers in patients with type 2 diabetes: A multicenter, randomized, double-blind, placebo-controlled study https://t.co/9DkZij89Gd

Sep 9, 2025 · 8 likes · 30,991 followers View post →
TimePie (focus on anti-aging science)
@TimePieChina · X

Diabetes drug shows anti-ageing effects on chromosomes.

Sep 8, 2025 · 3 likes · 1 share · 738 followers View post →
Cell Reports Medicine
@CellRepMed · X

Online now: Effect of henagliflozin on aging biomarkers in patients with type 2 diabetes: A multicenter, randomized, double-blind, placebo-controlled study https://t.co/OzKDZ4volL

Sep 8, 2025 · 2 likes · 18,951 followers View post →
Nobuhiro Ariyoshi MD
@AriyoshiMd · X

https://t.co/WJbqO4RNZ0

Sep 5, 2025 · 2 likes · 6,748 followers View post →
Cell Reports Medicine
@cp-cellrepmed.bsky.social · Bluesky

Online now: Effect of henagliflozin on aging biomarkers in patients with type 2 diabetes: A multicenter, randomized, double-blind, placebo-controlled study

Sep 5, 2025 · 2 likes View post →
Joe Scholar
@JScholar · X

Effect of henagliflozin on aging biomarkers in patients with type 2 diabetes: A multicenter, RCT: Cell Reports Medicine https://t.co/s7sC7Tip8b חוץ מהפרשת גלוקוז בשתן הגנה על הכליה ועל הלב בחולי סכרת האם מעכבי SGLT2 מאריכים גם טלומרים ומעכבים זיקנה?

Sep 5, 2025 · 1 like · 1,278 followers View post →

All mentions

Nutriop Longevity
@nutriop · X

Effect of henagliflozin on aging biomarkers in patients with type 2 diabetes: A multicenter, randomized, double-blind, placebo-controlled study - https://t.co/bU4Rn6hi33 https://t.co/rO2HLzntQC

Oct 4, 2025 · 81 followers View post →
WinAlly
@WinAlly_com · X

Effect of #henagliflozin on aging biomarkers in patients with type 2 diabetes: A multicenter, randomized, double-blind, placebo-controlled study #antiaging #winally #dna https://t.co/AMxZKjGVa2

Sep 11, 2025 · 860 followers View post →
wafy fahim
@wafyfahim1 · X

Effect of henagliflozin on aging biomarkers in patients with type 2 diabetes: A multicenter, randomized, double-blind, placebo-controlled study https://t.co/8INWPMTA1y

Sep 9, 2025 · 60 followers View post →
Aging Science News
@agingbiology.bsky.social · Bluesky

Effect of henagliflozin on aging biomarkers in patients with type 2 diabetes: A multicenter, randomized, double-blind, placebo-controlled study www.cell.com/cell-reports...

Sep 9, 2025 View post →
Aging Science News
@AgingBiology · X

Effect of henagliflozin on aging biomarkers in patients with type 2 diabetes: A multicenter, randomized, double-blind, placebo-controlled study https://t.co/9DkZij89Gd

Sep 9, 2025 · 8 likes · 30,991 followers View post →
新しい天使
@neostenshi · X

【ヘナグリフロジンに抗老化作用】SGLT2阻害薬ヘナグリフロジンは2型糖尿病患者のテロメアを延長させることが判明

Sep 9, 2025 · 4,089 followers View post →
Tommy Jaxon
@HealthyAI_TJ · X

RT @TimePieChina: Diabetes drug shows anti-ageing effects on chromosomes.

Sep 9, 2025 · 1 share · 36 followers View post →
TimePie (focus on anti-aging science)
@TimePieChina · X

Diabetes drug shows anti-ageing effects on chromosomes.

Sep 8, 2025 · 3 likes · 1 share · 738 followers View post →
Cell Reports Medicine
@CellRepMed · X

Online now: Effect of henagliflozin on aging biomarkers in patients with type 2 diabetes: A multicenter, randomized, double-blind, placebo-controlled study https://t.co/OzKDZ4volL

Sep 8, 2025 · 2 likes · 18,951 followers View post →
imquang
@imquang · X

Effect of henagliflozin on aging biomarkers in patients with type 2 diabetes: A multicenter, randomized, double-blind, placebo-controlled study - ScienceDirect https://t.co/hqBRVMFvu0

Sep 7, 2025 · 78 followers View post →
C Mak
@onlineadguy · X

Effect of henagliflozin on aging biomarkers in patients with type 2 diabetes: A multicenter, randomized, double-blind, placebo-controlled study: Cell Reports Medicine https://t.co/Reb4gAi0ll

Sep 7, 2025 · 213 followers View post →
CitizenKC
@CitizenKC53 · X

@Dr_Singularity The report misspells the drug name. It's henagliflozin. One study, 150 participants over 26 weeks. Not yet replicated. Be very cautious. https://t.co/xW5HMtnc5W

Sep 6, 2025 · 1 like · 365 followers View post →
J. Ashby
@JacAshby · X

@MyTZus @Nature Here is the article: https://t.co/3n3dp9lK52

Sep 5, 2025 · 1 like · 243 followers View post →
Joe Scholar
@JScholar · X

Effect of henagliflozin on aging biomarkers in patients with type 2 diabetes: A multicenter, RCT: Cell Reports Medicine https://t.co/s7sC7Tip8b חוץ מהפרשת גלוקוז בשתן הגנה על הכליה ועל הלב בחולי סכרת האם מעכבי SGLT2 מאריכים גם טלומרים ומעכבים זיקנה?

Sep 5, 2025 · 1 like · 1,278 followers View post →
Nobuhiro Ariyoshi MD
@AriyoshiMd · X

https://t.co/WJbqO4RNZ0

Sep 5, 2025 · 2 likes · 6,748 followers View post →
Cell Reports Medicine
@cp-cellrepmed.bsky.social · Bluesky

Online now: Effect of henagliflozin on aging biomarkers in patients with type 2 diabetes: A multicenter, randomized, double-blind, placebo-controlled study

Sep 5, 2025 · 2 likes View post →